References

Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

10.3350/cmh.2024.0438 · 2025 · External reference

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

10.1016/j.jhep.2023.06.003 · 2023 · External reference

A review of the therapeutic effects of polyphenols on non-alcoholic fatty liver disease: focus on oxidative stress

10.18502/abi.v2i1.16242 · 2024 · External reference

Perspectives on precision medicine approaches to NAFLD diagnosis and management

10.1007/s12325-021-01690-1 · 2021 · External reference

Current status of liver transplantation in Europe

10.1016/j.ijsu.2020.05.062 · 2020 · External reference

Recent advances in nanodelivery systems for polyphenols in metabolic dysfunction-associated steatotic liver disease (MASLD): an update

2025 · External reference

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

10.3389/fcell.2024.1433857 · 2024 · External reference

Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs

10.3390/biomedicines13010135 · 2025 · External reference

From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework

10.3390/biom15020213 · 2025 · External reference

The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases

10.1016/j.cca.2021.10.018 · 2021 · External reference

Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment

10.1016/s2213-8587(24)00318-8 · 2025 · External reference

Interactions between Genetic and Environmental Risk Factors in Lifestyle Diseases

2025 · External reference

Environmental pollutants and metabolic disorders: the multi-exposure scenario of life

10.3389/fendo.2018.00582 · 2018 · External reference

Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability

10.1016/j.pharmthera.2015.03.005 · 2015 · External reference

P4 medicine: how systems medicine will transform the healthcare sector and society

2013 · External reference

Precision oncology: transforming cancer care through personalized medicine

10.1007/s12032-025-02817-y · 2025 · External reference

Molecular mechanisms in MASLD/MASH-related HCC

10.1097/hep.0000000000000786 · 2025 · External reference

Advancements in personalized medicine for Leukemia: integrating genetic, transcriptomic, and artificial intelligence insights

10.2174/0113816128402252251005215721 · 2025 · External reference

Precision medicine in colorectal cancer: leveraging multi-omics, spatial omics, and artificial intelligence

10.1016/j.cca.2024.119686 · 2024 · External reference

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity

10.3748/wjg.v24.i15.1601 · 2018 · External reference

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease

2020 · External reference

Predictive, personalized, preventive, participatory (P4) cancer medicine

10.1038/nrclinonc.2010.227 · 2011 · External reference

Recent advances in nonalcoholic fatty liver disease metabolomics

10.3350/cmh.2021.0127 · 2021 · External reference

Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update

10.1016/j.cgh.2024.05.052 · 2024 · External reference

Precision medicine in nonalcoholic fatty liver disease: new therapeutic insights from genetics and systems biology

10.3350/cmh.2020.0136 · 2020 · External reference

siRNA-mediated gene silencing for non-alcoholic fatty liver disease: a comprehensive review of molecular targets

10.1016/j.eurpolymj.2024.112866 · 2024 · External reference

Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches

10.1186/s40001-024-01708-8 · 2024 · External reference

A protein-truncating HSD17B13 variant and protection from chronic liver disease

10.1056/nejmoa1712191 · 2018 · External reference

Kurbasic, predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI

2020 · External reference

Clinical use of current polygenic risk scores may exacerbate health disparities

10.1038/s41588-019-0379-x · 2019 · External reference

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

10.1038/s41588-022-01078-z · 2022 · External reference

Performance of noninvasive tests of fibrosis among Asians, Hispanic, and non-Hispanic whites in the STELLAR trials

10.1016/j.cgh.2022.01.015 · 2023 · External reference

Gender differences in nonalcoholic fatty liver disease

2022 · External reference

NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk

10.1007/s12325-017-0556-1 · 2017 · External reference

Precision non-alcoholic fatty liver disease (NAFLD) diagnosis: leveraging ensemble machine learning and gender insights for cost-effective detection

2024 · External reference

Sex differences in mortality and liver-related events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

10.1111/liv.15910 · 2024 · External reference

Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms

2020 · External reference

A machine learning based framework to identify and classify non-alcoholic fatty liver disease in a large-scale population

2022 · External reference

Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race

10.1002/oby.23960 · 2024 · External reference

Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation

10.3389/fendo.2024.1450317 · 2024 · External reference

Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications

10.1016/j.ajhg.2024.03.003 · 2024 · External reference

A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement

10.1016/j.jhep.2020.03.039 · 2020 · External reference

MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

10.1053/j.gastro.2019.11.312 · 2020 · External reference

Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III

10.1136/bmjopen-2022-067203 · 2022 · External reference

Navigating liver health with metabolomics: A comprehensive review

10.1016/j.cca.2024.120038 · 2025 · External reference

Multiple machine learning identifies key gene PHLDA1 suppressing NAFLD progression

10.1007/s10753-024-02164-6 · 2025 · External reference

Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis

2024 · External reference

Microarray-based detection of critical overexpressed genes in the progression of hepatic fibrosis in non-alcoholic fatty liver disease: A protein-protein interaction network analysis

10.2174/0929867330666230516123028 · 2024 · External reference

NIS2+™, An optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: a prospective derivation and validation study

2023 · External reference

Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)

10.1097/hep.0000000000000542 · 2023 · External reference

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD

2024 · External reference

Obesity, metabolism, large-scale plasma proteomics improves prediction of major adverse liver outcomes in individuals with MASLD

2026 · External reference

Association of per-and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults

2023 · External reference

Association between per-and poly-fluoroalkyl substances and nonalcoholic fatty liver disease: a nested case-control study in northwest China

10.1016/j.envpol.2024.123937 · 2024 · External reference

Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults

2023 · External reference

DNA methylation and target gene expression in fatty liver progression from simple steatosis to advanced fibrosis

2025 · External reference

Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration

2025 · External reference

Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD

10.1016/j.celrep.2025.115350 · 2025 · External reference

Circulating histones as potential biomarkers of MASLD-MASH-HCC progression

2025 · External reference

Multicenter collaborative study to optimize mass spectrometry workflows of clinical specimens

2023 · External reference

A generative AI framework unifies human multi-omics to model aging, metabolic health, and intervention response

2026 · External reference

Validation of two LCHRMS methods for large-scale untargeted metabolomics of serum samples: strategy to establish method fitness-for-purpose

10.1016/j.chroma.2024.465230 · 2024 · External reference

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

10.1038/ng.257 · 2008 · External reference

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

10.1038/ng.2901 · 2014 · External reference

Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis

10.1155/2019/2096161 · 2019 · External reference

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

10.1002/hep.23050 · 2009 · External reference

Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis

10.1177/17562848211062807 · 2021 · External reference

Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database

10.4254/wjh.v13.i10.1417 · 2021 · External reference

Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics

10.1186/s12967-025-06387-5 · 2025 · External reference

Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: evidence from two observational studies

10.1007/s10238-026-02163-x · 2026 · External reference

Machine-learning algorithm for predicting fatty liver disease in a Taiwanese population

10.3390/jpm12071026 · 2022 · External reference

Use of machine learning to predict onset of NAFLD in an all-comers cohort-development and validation in 2 large Asian cohorts

10.1016/j.gastha.2024.06.007 · 2024 · External reference

Application of quantitative ultrasonography and artificial intelligence for assessing severity of fatty liver: A pilot study

2024 · External reference

Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat with radiofrequency ultrasound data using one-dimensional convolutional neural networks

10.1148/radiol.2020191160 · 2020 · External reference

Image-based AI diagnostic performance for fatty liver: a systematic review and meta-analysis

10.1186/s12880-023-01172-6 · 2023 · External reference

Advancing AI-assisted US screening for fatty liver

10.1148/radiol.232442 · 2023 · External reference

Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI

10.1007/s00261-025-05317-9 · 2026 · External reference

Artificial intelligence in nonalcoholic fatty liver disease: A new frontier in diagnosis and treatment

10.1002/cld.1071 · 2021 · External reference

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis

10.1038/s41591-024-03301-2 · 2025 · External reference

Artificial intelligence in precision medicine in hepatology

10.1111/jgh.15415 · 2021 · External reference

Machine learning survival models for non-alcoholic fatty liver disease based on a health checkup cohort

10.1186/s12876-025-04120-6 · 2025 · External reference

Diagnostic of fatty liver using radiomics and deep learning models on non-contrast abdominal CT

2025 · External reference

Transfer learning with pre-trained deep convolutional neural networks for the automatic assessment of liver steatosis in ultrasound images

2021 · External reference

A machine learning-based predictive model discriminates nonalcoholic steatohepatitis from nonalcoholic fatty liver disease

10.1016/j.heliyon.2024.e38848 · 2024 · External reference

Biological and clinical role of TREM2 in liver diseases

10.1097/hc9.0000000000000578 · 2024 · External reference

Effect of curcumin on attenuation of liver cirrhosis via genes/proteins and pathways: A system pharmacology study

10.3390/nu14204344 · 2022 · External reference

Target deconvolution of fenofibrate in nonalcoholic fatty liver disease using bioinformatics analysis

10.1155/2021/3654660 · 2021 · External reference

Effect of calebin-A on critical genes related to NAFLD: A protein-protein interaction network and molecular docking study

10.2174/0113892029280454240214072212 · 2024 · External reference

Statins as a potential treatment for non-alcoholic fatty liver disease: target deconvolution using protein-protein interaction network analysis

10.2174/0929867331666230829164832 · 2025 · External reference

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials

10.1016/j.jhep.2024.12.046 · 2025 · External reference

Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis

10.1016/j.jhep.2025.05.031 · 2025 · External reference

A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis

10.1056/nejmoa2309000 · 2024 · External reference

Phase 3 trial of Semaglutide in metabolic dysfunction-associated steatohepatitis

10.1056/nejmoa2413258 · 2025 · External reference

PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease

10.1111/jgh.12656 · 2015 · External reference

Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]

10.1016/j.cct.2014.02.002 · 2014 · External reference

Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial

10.1016/j.jhep.2015.07.036 · 2015 · External reference

Statin use and non-alcoholic steatohepatitis in at risk individuals

10.1016/j.jhep.2015.05.006 · 2015 · External reference

EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

10.1016/j.jhep.2024.04.031 · 2024 · External reference

Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care

10.1111/liv.16119 · 2025 · External reference

Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes

10.1001/jamanetworkopen.2025.42750 · 2025 · External reference

Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial

10.1038/s43856-025-00796-9 · 2025 · External reference

Non-alcoholic fatty liver and liver fibrosis predictive analytics: risk prediction and machine learning techniques for improved preventive medicine

10.1007/s10916-020-01693-5 · 2021 · External reference

Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics

10.1016/j.metabol.2018.08.002 · 2018 · External reference

Application of artificial intelligence for the diagnosis and treatment of liver diseases

10.1002/hep.31603 · 2021 · External reference